Clinical Trial Update: Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial update for ataluren in nonsense mutation-related CDKL5 and Dravet syndrome (epilepsy) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cdkl5 Deficiency Disorder
• Dravet Syndrome
• Epilepsy

Drugs mentioned

• ataluren (ataluren)

Snippet

Sponsor: NYU Langone Health | Conditions: Epilepsy | Phase 2 | Status: COMPLETED | Results posted: 2023-02-16